Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic (OBVIONCO)
Oncology, COVID-19
About this trial
This is an interventional other trial for Oncology
Eligibility Criteria
Inclusion Criteria:
- Patient over 18 years of age
- Patient followed in the medical oncology department of Paris Saint-Joseph Hospital Paris in France
- Patient Having regular access to smartphone and internet sufficient to support study demands
- French-speaking patient
- Affiliation to the social security network
- Willing and able to provide given oral, free, informed and express consent
Exclusion Criteria:
- Patients unable or unwilling to perform all requested study tasks
- Patient under tutorship or curatorship
- Patient deprived of liberty
- Pregnant or lactating patient
Sites / Locations
- Groupe Hospitalier Paris Saint-Joseph
Arms of the Study
Arm 1
Experimental
Obvio-19 App
If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. After enrollment, patients will be sent an invitation via email to download the Obvio-19 mobile app. After downloading the Obvio-19 app, patients will receive instructions as to how they may communicate with the study investigator. Communication may occur through the chat function of the app or live telephone conversations. Patients must log into the Obvio-19 app daily to complete the questionnaires. The Obvio-19 system is designed to identify responses that indicate the participant is at an increased risk for serious illness or exhibiting serious symptoms, such as coughing up blood. Such patients will be notified by the app of this status and prompted to seek medical attention.